I guess we have to agree to disagree on which drug is more valuable right now. Stemcentrx's Phase 1 cancer drug was acquired by AbbVie for $5.8B (up to $10.2B). It'll be great if you can show me a Phase 2 psoriasis drug being acquired for a greater amount.

http://www.businessinsider.com/stemcentrx-rov...r%20Select

Quote:

---

I was trying to say that P is more valuable than K RIGHT NOW.

---